GlassScriptPhysician profile
Nitika Sharma
NPI 1043631773
$6,603.49
in general payments reported to CMS, 2019-2025
34 companies · $4,960 in 2025
The $4,960 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,237 · 2020: $307 · 2021: $29.59 · 2022: $11.78 · 2023: $20.18 · 2024: $37.29 · 2025: $4,960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,960 · Food and Beverage: $57.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,960.00 |
| Food and Beverage | $57.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $4,960.00 | 2025 | Orserdu |
| E.R. Squibb & Sons, L.L.C. | $261.33 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $229.59 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $129.61 | 2019-2020 | |
| Genentech USA, INC. | $80.90 | 2019-2020 | |
| Celgene Corporation | $73.92 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $71.38 | 2019 | |
| Pfizer INC. | $67.38 | 2019 | |
| Amgen INC. | $65.08 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.03 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $55.91 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.83 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.04 | 2019 | |
| Alexion Pharmaceuticals, INC. | $44.71 | 2019-2020 | |
| Lilly USA, LLC | $42.89 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $36.42 | 2023-2024 | |
| Exelixis INC. | $35.17 | 2019 | |
| Jazz Pharmaceuticals INC. | $32.86 | 2019 | |
| Seagen INC. | $28.87 | 2019-2020 | |
| Myriad Genetic Laboratories, INC. | $21.05 | 2024 | Precisetumor |
| Coherus Oncology, INC. | $20.04 | 2020 | |
| Tesaro, INC. | $19.35 | 2019 | |
| Daiichi Sankyo INC. | $19.05 | 2020 | |
| Shire North American Group INC | $18.21 | 2019 | |
| Genzyme Corporation | $17.75 | 2019 | |
| Janssen Biotech, INC. | $17.20 | 2019 | |
| Astellas Pharma US INC | $16.15 | 2019 | |
| Rigel Pharmaceuticals, INC. | $15.32 | 2019 | |
| Btg International INC. | $13.36 | 2019 | |
| Eisai INC. | $12.98 | 2019 | |
| Kyowa Kirin, INC. | $11.90 | 2019 | |
| Emd Serono, INC. | $11.40 | 2020 | |
| Secura Bio, INC. | $9.81 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitika Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.